US · FDA approval, new medicineGepotidacin (Blujepa)To treat uncomplicated urinary tract infectionsApproved 25 Mar 2025Source: US Food and Drug Administration
Infectious diseases · Clin Infect Dis · 2026-10-28Secondary analysis of two pooled phase 3 trials in females with uncomplicated UTI: therapeutic success favoured gepotidacin over nitrofurantoin by 9.6% (susceptible) and 20.8% (non-susceptible uropathogens); clinical success gaps non-significant.Secondary analysisSheets et al. Subgroup Analysis of Pooled Phase 3 Efficacy Data From Two Randomized Trials of Gepotidacin Versus Nitrofurantoin in Uncomplicated Urinary Tract Infections (EAGLE-2 and EAGLE-3) Including Participants With Uropathogens Not-Susceptible to Nitrofurantoin
Infectious diseases · Clin Infect Dis · 2026-04-30Secondary pooled analysis of two phase 3 RCTs (3136 participants) in uncomplicated UTI: gepotidacin and nitrofurantoin gave similar early symptom relief; 53.2% vs 53.6% with moderate-severe symptoms reported no impact on daily activities on therapy.Secondary analysisn = 3,136Sheets et al. Early Symptom Response in Patients With Uncomplicated Urinary Tract Infection Treated With Gepotidacin or Nitrofurantoin: Pooled Analysis From Two Pivotal Phase 3 Studies
Infectious diseases · J Antimicrob Chemother · 2026-01-19Meta-analysis of 3 RCTs (3510 women with uncomplicated UTI): gepotidacin vs nitrofurantoin increased composite therapeutic success (RR 1.20, 95% CI 1.10-1.31) and microbiological eradication (RR 1.14), but diarrhoea (RR 5.51) and nausea (RR 2.49) were more frequent.Meta-analysisn = 3,510Ibrahim et al. Safety and efficacy of gepotidacin in urinary tract infection: a GRADE-assessed systematic review and meta-analysis